These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9891826)

  • 21. Guidelines for choosing drugs in chronic heart failure.
    Tabrizchi R
    Vasc Health Risk Manag; 2005; 1(3):171-2. PubMed ID: 17319102
    [No Abstract]   [Full Text] [Related]  

  • 22. Drugs for treatment of heart failure.
    Treat Guidel Med Lett; 2006 Jan; 4(41):1-4. PubMed ID: 16374402
    [No Abstract]   [Full Text] [Related]  

  • 23. Are you missing your "must-use" medications?
    Harv Heart Lett; 2003 Apr; 13(8):6-7. PubMed ID: 12711577
    [No Abstract]   [Full Text] [Related]  

  • 24. Beta blockers and the failing heart: is it time for a U-turn?
    Bashir Y; McKenna WJ; Camm AJ
    Br Heart J; 1993 Jul; 70(1):8-12. PubMed ID: 7913613
    [No Abstract]   [Full Text] [Related]  

  • 25. Beta-receptor polymorphisms: heart failure's crystal ball.
    Kass DA
    Nat Med; 2003 Oct; 9(10):1260-2. PubMed ID: 14520373
    [No Abstract]   [Full Text] [Related]  

  • 26. A cost minimisation analysis of cardiac failure treatment in the UK using CIBIS trial data. Cardiac Insufficiency Bisoprolol Study.
    Malek M; Cunningham-Davis J; Malek L; Paschen B; Tavakoli M; Zabihollah M; Davey P
    Int J Clin Pract; 1999; 53(1):19-23. PubMed ID: 10344061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006.
    Jessup M; Banner N; Brozena S; Campana C; Costard-Jäckle A; Dengler T; Hunt S; Metra M; Rahmel A; Renlund D; Ross H; Warner Stevenson L
    J Heart Lung Transplant; 2006 Sep; 25(9):1003-23. PubMed ID: 16962463
    [No Abstract]   [Full Text] [Related]  

  • 28. Beta-blockers influence the short-term and long-term prognostic information of natriuretic peptides and catecholamines in chronic heart failure independent from specific agents.
    Frankenstein L; Nelles M; Slavutsky M; Schellberg D; Doesch A; Katus H; Remppis A; Zugck C
    J Heart Lung Transplant; 2007 Oct; 26(10):1033-9. PubMed ID: 17919624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Ongoing Evolution of Optimal Clinical Endpoints for Heart Failure Trials.
    Krum H; Hopper I
    JACC Heart Fail; 2015 Aug; 3(8):615-7. PubMed ID: 26251087
    [No Abstract]   [Full Text] [Related]  

  • 30. Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure.
    Feldman DS; Carnes CA; Abraham WT; Bristow MR
    Nat Clin Pract Cardiovasc Med; 2005 Sep; 2(9):475-83. PubMed ID: 16265588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reassessing guidelines for heart failure.
    Drexler H; Wollert KC
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S28-33. PubMed ID: 15526240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obstacles to the initiation of beta blockers for heart failure in a specialised clinic within a district general hospital.
    Mahmoudi M; McDonagh S; Poole-Wilson P; Dubrey SW
    Heart; 2003 Apr; 89(4):442-4. PubMed ID: 12639877
    [No Abstract]   [Full Text] [Related]  

  • 33. An overview of inotropic agents.
    Vroom MB
    Semin Cardiothorac Vasc Anesth; 2006 Sep; 10(3):246-52. PubMed ID: 16959760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. beta(3)-Adrenoceptor antagonism improves clinical outcomes of chronic heart failure.
    Wu T; Wang L
    Med Hypotheses; 2007; 69(5):1114-6. PubMed ID: 17428618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Would you give a beta-blocker and/or aldosterone antagonist to a patient with an ejection fraction (EF) of 30 who has never had symptoms of heart failure?
    Pitt B
    J Am Coll Cardiol; 2005 Jul; 46(1):CS6. PubMed ID: 16007749
    [No Abstract]   [Full Text] [Related]  

  • 36. Nebivolol for heart failure in the elderly.
    Tavazzi L
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):423-33. PubMed ID: 17489667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multifaceted intervention to promote beta-blocker use in heart failure.
    LaPointe NM; DeLong ER; Chen A; Hammill BG; Muhlbaier LH; Califf RM; Kramer JM
    Am Heart J; 2006 May; 151(5):992-8. PubMed ID: 16644320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ask the doctor. My father has severe heart failure. The doctors say his ejection fraction is only about 10%, and he gets short of breath during any physical activity. I've read that beta blockers are useful for heart failure, but his doctors say they're too risky for my father. I'm worried that he's missing out on a beneficial treatment.
    Lee TH
    Harv Heart Lett; 2001 Oct; 12(2):8. PubMed ID: 11684495
    [No Abstract]   [Full Text] [Related]  

  • 39. [Beta blockers in cardiac insufficiency. When, how much and which substance].
    Wuttke H; Rau T; Eschenhagen T
    Med Monatsschr Pharm; 2004 Dec; 27(12):415-20; quiz 421-2. PubMed ID: 15646690
    [No Abstract]   [Full Text] [Related]  

  • 40. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes.
    Gislason GH; Rasmussen JN; Abildstrom SZ; Schramm TK; Hansen ML; Buch P; Sørensen R; Folke F; Gadsbøll N; Rasmussen S; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2007 Aug; 116(7):737-44. PubMed ID: 17646585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.